Professor Zhu Biao: Impact of Single-Tablet HIV Medications B/F/TAF and E/C/F/TAF on Lipid Metabolism

Professor Zhu Biao: Impact of Single-Tablet HIV Medications B/F/TAF and E/C/F/TAF on Lipid Metabolism

2023.12.08
AIDS remains a significant global health concern, but recent advancements in medical technology have shifted the treatment of HIV-infected individuals toward a chronic disease management approach. Ensuring treatment safety and adherence is a critical challenge within this context. Currently, two single-tablet regimens, Biktarvy (B/F/TAF) and Descovy (E/C/F/TAF), are widely used globally, including in China, for managing HIV infections. These regimens not only effectively suppress the virus but also offer good safety and adherence rates. In recent years, concerns have arisen about complications related to HIV infection, particularly the increased risk of cardiovascular diseases (CVD) associated with long-term antiretroviral drug use. This risk significantly affects the life expectancy and long-term health of HIV-infected individuals. From October 18 to 20, 2023, the 19th European AIDS Conference (EACS 2023) was held in Warsaw, Poland. During the conference, a clinical study led by Professor Zhu Biao from the First Affiliated Hospital of Zhejiang University School of Medicine was featured as a poster presentation (Abstract No. 551). This study suggests that compared to E/C/F/TAF, B/F/TAF has a milder impact on lipid metabolism and is associated with a reduced risk of CVD.
Professor Lv Wei: An All-Encompassing Interpretation of Clinical Diagnosis and Treatment Strategies for Late-Diagnosed HIV Patients

Professor Lv Wei: An All-Encompassing Interpretation of Clinical Diagnosis and Treatment Strategies for Late-Diagnosed HIV Patients

2023.12.08
This article features an interview with Professor Lv Wei, offering a comprehensive analysis of the clinical diagnosis and treatment strategies for late-presenting HIV patients. This group is a significant challenge in China's HIV/AIDS prevention and treatment efforts due to their higher hospitalization and transmission rates, heavier economic burdens, and poorer long-term prognosis.
Pay attention to the comorbidities of the heart, lungs, and metabolic system in HIV infected individuals

Pay attention to the comorbidities of the heart, lungs, and metabolic system in HIV infected individuals

2023.12.08
Anti retroviral therapy (ART) significantly improves the life expectancy of HIV infected individuals. However, in recent years, the incidence rate of cardiovascular diseases and other complications related to obesity, type 2 diabetes, and metabolic syndrome (namely, abdominal obesity, hypertension, elevated triglyceride levels, dyslipidemia, and changes in blood glucose levels) has gradually increased among HIV infected people, which has become a growing concern. The complex interaction between sustained low-level immune activation, ART related metabolic toxicity, and non HIV related risk factors in chronic HIV infection may increase the risk of these comorbidities in HIV infected individuals. At the 19th European Conference on AIDS (EACS 2023), Professor Susanne Dam Nielsen of the University of Copenhagen, Denmark, made a special report on the study of non infectious complications among HIV infected people, focusing on the latest research progress of cardiovascular disease, pulmonary disease and metabolic system disease complications. Our reporter invited Professor Nielsen to conduct an in-depth interview on this topic at the conference.
CVD risks in women living with HIV

CVD risks in women living with HIV

2023.12.08
Hi there. My name is Chris Longenecker. I'm a cardiologist at the University of Washington in Seattle, Washington, USA. I specialize in the care of people living with HIV infection. For many years I've run a clinic focused on cardiovascular disease management and prevention of cardiovascular disease for people living with HIV, first in Cleveland, Ohio for many years and now in Seattle.
Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

2023.12.08
With continuous progress in HIV treatment, the mortality rate has significantly decreased, and new infections have stabilized. However, there is still a gap from the 2020 targets set by the United Nations Programme on HIV/AIDS. To control new HIV infections, a comprehensive use of behavioral and biomedical methods, including antiviral drugs for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), is crucial. This strategy aims to reduce HIV transmission and control new infections. The 19th European AIDS Conference (EACS 2023) was held in Warsaw, Poland, from October 18 to 20, 2023. At the conference, Professor Jean-Michel Molina from the University of Paris City, Saint Louis and Lariboisière Hospital, shared insights on the application and challenges of HIV PrEP and PEP.

Progress and Challenges in the Field of HIV/AIDS – The 19th EACS Conference Concludes Successfully

2023.12.08
The 19th European AIDS Conference (EACS 2023), a highly anticipated event in the field of HIV/AIDS, was held grandly in Warsaw, Poland, from October 18 to 20, 2023. The conference provided a robust platform for medical professionals and researchers in the HIV/AIDS field, facilitating a comprehensive and multi-faceted discussion on urgent issues in combating HIV/AIDS. It showcased numerous breakthrough clinical studies and honored outstanding contributors in the field. The conference offered a thorough and in-depth interpretation of the current status and future vision of global HIV/AIDS prevention and treatment.

What to start with? A review of current guidelines (EACS, WHO, DHHS)

2023.12.08
Hello. My name is Cristiana Oprea. I'm an infectious disease and HIV clinician at Victor Babes Hospital for infectious and tropical diseases in Bucharest, and also an associate professor at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. I am part of the European AIDS Clinical Society governing board since 2014, and also part of the EuroSida steering committee since 2017.

Integrase Inhibitors Do Not Increase Cardiovascular Event Risk in HIV Patients

2023.12.08
This article discusses a significant study presented at the 19th European AIDS Conference (EACS 2023), held in Warsaw, Poland, from October 18-20, 2023. Professor Bernard Surial from the University of Bern in Switzerland shared the results of an international cohort study, which revealed that the use of integrase strand transfer inhibitors (INSTIs) in the treatment of HIV does not increase the risk of cardiovascular events.